VasSol touts data on MRI-based blood flow measurement

VasSol said last week that results from a trial of its Nova non-invasive optimal vessel analysis showed that the device was able to identify critical trial patients at higher risk of recurrent stroke. The results from the study were published in the JAMA Neurology journal. Results from the 6-year, multi-center Veritas trial indicated that patients who experience a stroke in the back of their brain, and continue to have reduced blood flow to the area, have a higher risk of having another stroke within 2 years. “Nova is the only technology that can visualize and quantify the volume, speed and direction of blood flowing through any major vessel of the brain. Identifying those at highest risk for a stroke makes studying the condition easier and leads to better, more precise therapies and more focused implementation of healthcare resources,” chief science officer Dr. Fady Charbel said in a press release. VasSol said results from the trial are “expected to change the standard of care for posterior stroke victims,” who make up approximately 40% of all stroke victims. “We believe that Nova should be included in the clinical and imaging assessment of posterior circulation stroke patients. At Northwestern, we’re using it in the current Myriad trial to further broaden its application in stroke-risk diagnosis and treatment planning,” Dr. Shyam Prabhakaran of Northwestern University’s Feinberg School of Medicine said in a prepared statement. ...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Blood Management Clinical Trials Diagnostics Software / IT VasSol Source Type: news